: Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy. Main complications include the development of arrhythmias and heart failure, and the latter may be triggered by left ventricular outflow tract obstruction. The treatment of left ventricular outflow tract obstruction includes pharmacological therapies (beta-blockers, calcium channel blockers, disopyramide) and septal reduction therapies (alcohol septal ablation, surgical myectomy). Myosin inhibitors represent a new therapeutic opportunity and in recent clinical trials proved effective in symptom relief, improvement of functional capacity and quality of life in patients with obstructive hypertrophic cardiomyopathy. In this narrative review we will summarize the available and under development therapeutic approaches for hypertrophic cardiomyopathy.

[Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy] / Argirò, Alessia; Zampieri, Mattia; Marchi, Alberto; Del Franco, Annamaria; Pàlinkàs, Eszter Dalma; Biagioni, Giulia; Chiti, Chiara; Mazzoni, Carlotta; Fornaro, Alessandra; Targetti, Mattia; Cappelli, Francesco; Olivotto, Iacopo. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1972-6481. - STAMPA. - 24:(2023), pp. 792-799. [10.1714/4100.40979]

[Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy]

Zampieri, Mattia;Marchi, Alberto;Del Franco, Annamaria;Chiti, Chiara;Mazzoni, Carlotta;Fornaro, Alessandra;Targetti, Mattia;Cappelli, Francesco;Olivotto, Iacopo
2023

Abstract

: Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy. Main complications include the development of arrhythmias and heart failure, and the latter may be triggered by left ventricular outflow tract obstruction. The treatment of left ventricular outflow tract obstruction includes pharmacological therapies (beta-blockers, calcium channel blockers, disopyramide) and septal reduction therapies (alcohol septal ablation, surgical myectomy). Myosin inhibitors represent a new therapeutic opportunity and in recent clinical trials proved effective in symptom relief, improvement of functional capacity and quality of life in patients with obstructive hypertrophic cardiomyopathy. In this narrative review we will summarize the available and under development therapeutic approaches for hypertrophic cardiomyopathy.
2023
24
792
799
Argirò, Alessia; Zampieri, Mattia; Marchi, Alberto; Del Franco, Annamaria; Pàlinkàs, Eszter Dalma; Biagioni, Giulia; Chiti, Chiara; Mazzoni, Carlotta;...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1344533
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact